DANCANN PHARMA A/S: Financial statements 2024
CVR: 39426005
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
DANCANN PHARMA A/S (CVR 39426005) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -148,000 and a net result of DKK -8,346,000 compared with DKK -62,260,000 the year before. Equity in the 2024 report amounted to DKK 14,620,000. The solvency ratio was 91.5%. The company had 5 employees in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -148,000
- Profit/Loss
- DKK -8,346,000
- Equity
- DKK 14,620,000
- Total Assets
- DKK 15,974,000
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | 0 | -148 t. | -8.3 mio. | 14.6 mio. | 5 |
| 2023 | 0 | -5.3 mio. | -62.3 mio. | 9.5 mio. | 12 |
| 2022 | 0 | -7.6 mio. | -16.1 mio. | 62.8 mio. | 10 |
| 2021 | 0 | -6.8 mio. | -11.8 mio. | 53.4 mio. | 10 |
| 2020 | - | -4.8 mio. | -4.3 mio. | 44.3 mio. | 4 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of December 10, 2024, Jes Lunde has joined the board of directors of DANCANN PHARMA A/S.
As of December 10, 2024, is registered as an owner of DANCANN PHARMA A/S with an ownership share of 5%.
DANCANN PHARMA A/S has published its annual report for 2023. Revenue came to DKK 0, and the net result was DKK -62,260,000.
About DANCANN PHARMA A/S
DANCANN PHARMA A/S is a Danish company of the type Aktieselskab based in Ansager, founded in 2018. The company is under bankruptcy. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named DANCANN PHARMA ApS and DANCANN PHARMA IVS. The company is owned by JEQ Capital AB. The company has 1 employee (2026). In 2024, the company reported a gross profit of DKK -148,000 and a net result of DKK -8,346,000 compared with DKK -62,260,000 the year before. Equity in the 2024 report amounted to DKK 14,620,000.